Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-17T19:00:53.468Z Has data issue: false hasContentIssue false

Therapeutic options in panic disorder

Published online by Cambridge University Press:  16 April 2020

HGM Westenberg*
Affiliation:
Department of Biological Psychiatry, Academic Hospital Utrecht, PO Box 85500, Utrecht, NL-3508, The Netherlands
Get access

Extract

The principal management strategy for patients with panic attacks and agoraphobia has traditionally been behavioural therapy, but the delineation of panic disorder as a distinct diagnostic entity has stimulated psychopharmacological research on this psychiatric condition. As a result, the treatment of panic disorder has diversified. Effective pharmacological treatment of this disorder began with the antidepressant imipramine, but today a wide variety of efficacious agents are available for treating the symptoms of panic disorder. The four primary classes of agents for panic disorder are the tricyclic antidepressants (TCAs), the serotonin reuptake inhibitors (SSRIs), the monoamine oxidase inhibitors (MAOIs) and the high-potency benzodiazepines (BZs). Effective non-pharmacological treatments are primarily behavioural, although cognitive approaches have also been shown to be successful.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Submit a response

Comments

No Comments have been published for this article.